Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will aff...
Main Authors: | Hara, H, Hironaka, T, Inoue, M, Iida, A, Shu, T, Hasegawa, M, Nagai, Y, Falsey, A, Kamali, A, Anzala, O, Sanders, E, Karita, E, Mwananyanda, L, Vasan, S, Lombardo, A, Parks, C, Sayeed, E, Krebs, M, Cormier, E, Ackland, J, Price, M, Excler, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2011
|
Similar Items
-
Sendai virus-mediated CFTR gene transfer to the airway epithelium.
by: Ferrari, S, et al.
Published: (2007) -
Characterization of the phospholipid and fatty acid composition of Sendai virus.
by: J A Barnes, et al.
Published: (1987-02-01) -
Trafficking of Sendai virus nucleocapsids is mediated by intracellular vesicles.
by: Raychel Chambers, et al.
Published: (2010-06-01) -
Structure and assembly of double-headed Sendai virus nucleocapsids
by: Na Zhang, et al.
Published: (2021-04-01) -
Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses
by: Charles J. Russell, et al.
Published: (2021-05-01)